Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX in advanced or metastatic neuroendocrine carcinoma
NCT03279614Phase 2Unknown
- Sponsor
- Peking University
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin and tegafur in neuroendocrine carcinoma (NEC), sponsored by Peking University. Status: unknown.
02
Drugs
oxaliplatintegafur
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03279614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279614.